share_log

Goldman Sachs Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $7

Benzinga ·  Oct 8 22:19  · Ratings

Goldman Sachs analyst Matthew Sykes maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and lowers the price target from $8 to $7.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment